To summary, in the present meta-analysis we found that XPD Lys751Gln polymorphism was not associated with clinical outcomes of Pt-chemotherapy in NSCLC, while the XPD Asp312Asn polymorphism could predict poor response to Pt-chemotherapy, favorable survival in Caucasian but unfavorable survival in Asian population. Here, ERCC2 is linked to non-small cell lung carcinoma.